Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.

Abstract	Omalizumab is a unique biologic therapeutic drug approved for treating atopic patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. This study was performed to examine the efficacy of omalizumab for the treatment of atopic dermatitis (AD), a disease with significant morbidity. A prospective analysis was performed to assess the efficacy of omalizumab in 21 patients with moderate to severe persistent allergic asthma and AD. Patients were stratified into the following groups: very high IgE (>700 IU/mL), high IgE (186-700 IU/mL), and normal IgE (0-185 IU/mL). AD severity was assessed at 0, 1, 3, 6, and 9 months via an Investigator Global Assessment index. Twenty-one patients (14-64 years old) were evaluated. Pretreatment IgE levels ranged from 18.2 to 8396 IU/mL, (mean IgE level was 1521 IU/mL). All 21 patients showed clinical and statistically significant improvement of their atopic dermatitis (p<0.00052). In conclusion, this study indicates that omalizumab is effective in treating AD in patients with moderate to severe persistent allergic asthma.
Authors	Lee E Sheinkopf, Asif W Rafi, LanAnh T Do, Roger M Katz, William B Klaustermeyer
Journal	Allergy and asthma proceedings (Allergy Asthma Proc) 2008 Sep-Oct Vol. 29 Issue 5 Pg. 530-7 ISSN: 1088-5412 [Print] United States
PMID	18926061 (Publication Type: Journal Article)
Chemical References	Anti-Allergic Agents Antibodies, Anti-Idiotypic Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Omalizumab Immunoglobulin E
Topics	Adolescent Adult Anti-Allergic Agents (administration & dosage, therapeutic use) Antibodies, Anti-Idiotypic Antibodies, Monoclonal (administration & dosage, therapeutic use) Antibodies, Monoclonal, Humanized Asthma (complications) Dermatitis, Atopic (complications, drug therapy) Female Humans Immunoglobulin E (blood) Male Middle Aged Omalizumab Pilot Projects Prospective Studies Severity of Illness Index Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!